Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

Abstract

Potential conflict of interest: Listed at the end of the article for all authors. These recommendations have been approved by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Potential conflict of interest: Listed at the end of the article for all authors. All AASLD Practice Guidelines are updated annually. If you are viewing a Practice Guideline that is more than 12 months old, please visit www.aasld.org for an update in the material. Preamble The pace of hepatitis C virus (HCV) drug development in recent years has accelerated dramatically. For patients to benefit from these impressive advances, practitioners need access to the most up‐to‐date data and to advice from experienced experts. Such information and advice can be difficult to access readily given the diverse sources from which information is available and the sometimes lengthy time needed for publication of original articles and scholarly perspectives. Traditional practice guidelines for more established areas of medicine and care often take years to develop and bring to publication. In the new era in hepatitis C treatment, such a process would not be nimble or timely enough to address the needs of patients with HCV infection, practitioners caring for these patients, or payers approving therapies for use. A living document made available in a web‐based system, such as that used by the US Department of Health and Human Services for human immunodeficiency virus (HIV) treatment recommendations (http://aidsinfo.nih.gov/guidelines), was selected as the best model to provide timely recommendations for hepatitis C management. In 2013, the two major membership societies supporting liver and infectious disease specialists (American Association for the Study of Liver Diseases [AASLD] and Infectious Diseases Society of America [IDSA]) joined forces to develop guidance for the management of hepatitis C in this rapidly moving field. The International Antiviral Society‐USA, which has experience in developing treatment guidelines in HIV disease, was invited to join the effort as a collaborating partner responsible for managing the panel and the guidance development process. The goal of the hepatitis C guidance is to provide up‐to‐date recommendations for HCV care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, using a rigorous review process to evaluate the best available evidence. This review provides a condensed summary of recommendations from the guidance. The complete guidance, which is updated regularly, is available at www.hcvguidelines.org. Process This was conceived to be a living document that would reside online and undergo real‐time revisions as the field evolved. To lead the process, two cochairs selected by the governing boards of each founding society were joined by a fifth cochair representing the International Antiviral Society‐USA. These cochairs selected 10 panel members from each society. The panel members were chosen to represent expertise in the diagnosis, management, treatment, research, and patient care from the fields of hepatology and infectious diseases. At least 51% of the panelists could have no substantive industry support other than research advisory boards, data safety monitoring boards, or research funding that went to the member's employer. The panel first convened in person in October 2013. Panel members were divided into teams to review available data and to propose preliminary guidance in three areas: (1) testing and linkage to care, (2) initial treatment of HCV infection, and (3) retreatment of patients in whom prior HCV treatment had failed. The treatment section teams data for in patients with hepatitis with with and had liver The teams and cochairs by All panel members and approved the governing the The first of the guidance was on three were (1) treatment of HCV infection, (2) monitoring and and (3) and whom to In October the panel in person to update recommendations to data on new The updated recommendations revisions of all were on This was on for the guidance was by the AASLD and the industry funding was or The for and funding for and data to testing and linkage to and the The in the fields of hepatology and infectious used an to review available information for the guidance. sources were research in or at major or research safety from the US and other or the drug information from and data for new initial of the on 2013. To be articles needed to be in from to the using or and in were Panel members the and other sources and update the guidance as new is in of the of by or and the of the by or using a from the American of and the American Association Practice by and of for which is that a given or treatment is and for which is a of the and of a or treatment of is in of and and are established by for which is that a or treatment is not and or in be of from or from a or C of or of care such as for HCV with an or be The has or For and In for which was a panel members the as to a for A and from the American of and the American Association Practice HCV and to the to with HCV in the United States, are that are of with infection is the first and HCV testing is in on prior and In the HCV testing guidelines in with a to a HCV to all from of HCV have been This was by the of the to more than of HCV in the to for of all HCV with a than other A review that of with HCV infection would have been a testing would have been with the The of testing is to that of of for for HCV the years of and or drug a in an Health care, and safety or to to of or were that from a for HCV infection a of or or an were HIV infection liver disease and hepatitis and with the and the US Services a HCV is in in the and other on and that for HCV for HCV be using such as testing for with or a A HCV infection or infection that has or a or testing with a of or be used to HCV to HCV infection and management. for HCV be in with a are or have been to HCV in the prior months these be HCV is needed to in or for of and testing can be in the testing at www.hcvguidelines.org. All for HCV testing first be for using an be by testing for HCV the optimal of testing in at for to HCV is the of testing on the of of the of HCV infection and have with have at least HCV testing is in these HCV testing is for and for have with testing be to other at of HCV with HCV be to is of the of which lead to more of liver and the development of with HCV be for HIV and hepatitis as with hepatitis virus or HIV has been with of and from and and with and have are more to have liver disease, which in are or by a of or or or be to and and with HCV be disease and to to in of hepatitis C and in treatment have on and patients have access to In the United States, is that of with HCV infection in to practitioners are and to evaluate such patients and provide treatment is or is that all patients with hepatitis C and a HCV be to and by a with expertise in the of liver disease and HCV with or management, of liver as by a is to provide management, of is for all with HCV and in to HCV hepatitis C treatment is in all patients and is by a as the of HCV for 12 or more of is a for of HCV infection and has been to be in in more than of patients for at least are of HCV infection experience a in liver of in most and of in the and other of liver disease is with a more than in the of liver and a in the of and liver of HCV infection and from a to of with HCV with and other complete or in to of HCV These in disease to in patients an have of and treatment for all with than 12 to treatment is best in the of the disease and the development of the most of treatment be by at for the to all patients as is most to first at of disease and at for HCV or in whom treatment such of treatment for in and is patients with liver disease or or with of and in HCV to the and for treatment to for or A or with or for treatment to for virus C liver disease C C to the and of with to of treatment in these of HCV or in have with with on of to care C at of HCV be on to and the of that in patients with the of an In a patients with or by were for more than The was in experienced an than in treatment had or were and and for of of other benefit treatment is at prior to Antiviral treatment is for all patients with HCV infection, with to If the to all patients as is most to at of disease with disease of is in the for treatment, in the of treatment, and the need for more The of is of the most used to disease and In to in more need for with for and are to with such as with of or or not the of patients testing to liver is the and In the is and are patient and such as are to the of in patients with HCV infection such as and of the by and liver is to have and the of each be The most to is to and liver of testing or liver is in to the of the of of HCV This section treatment of patients with hepatitis C are to of and are approved by the for HCV the initial for patients are with HCV has been by using are as and the of which to of drug the and For the of and has a with the of and has a with the and other that with the with HCV to have than patients with HCV with HCV infection that be be as For HCV patients, are three of and and For the of and the of for with not have The of is for than to for or The safety of each of these are than of patients treatment and were in with and HCV were the had treatment with and than not the in these patients, of the other for be for patients with HCV are are in of for 12 of and for 12 or with or for 12 or for patients with a for the using available In patients with HCV and have the of the other for is For HCV patients, are three of for 12 for 12 and with or for 12 for patients with for patients with HCV are are in of for 12 of for 12 with or for 12 or is the for patients with HCV more data are treatment to in HCV patients with is for patients with HCV and for 12 treatment to is for patients with is the most difficult to with available for is the in the United on recent data from a than with and for the of and for 12 is for the and monitoring of this a for 12 has been is not for patients with HCV and for 12 for and for for For the treatment of patients with HCV three are of with or the in and in of HCV be data are for patients with HCV infection in of for 12 of and for 12 and for and for 12 with or for 12 or data are available to for patients with HCV or on is for patients with HCV or of for 12 and for 12 for patients are of in of and a are in this and and In patients with treatment with for than 12 of treatment, supporting the that HCV patients with of with given for 12 to of in patients with in whom a prior of and or had failed. For patients with are with and of is patients with are with of The treatment in this are or For with in whom a prior has the recommendations for treatment are the as for patients with the treatment of can be to 12 and can be for retreatment of patients with HCV in whom and treatment had in HCV of for 12 of and for 12 for 12 HCV of for 12 of for 12 for 12 HCV or of for of of for 12 of of and for or for 12 with or for for patients with a for the using available and for HCV In patients with HCV and have the of the other for is of and and a and of or The treatment for patients with HCV in whom a prior that or has is for 12 For patients with were in the than the treatment patients with have treatment to In a retreatment of patients with treatment with and or were 12 of and and of and for 12 is for patients with in whom prior treatment with and and or are data for and treatment on of treatment with be given to this of patients as with and or be for retreatment of patients with HCV in whom a and had in in each for 12 of for of for 12 of of with to be more in with HCV than with and more in with than in of is with to and other HCV such as are data for retreatment a treatment with a of other with is for prior and or prior and to the of data in this to a be for For patients with liver disease, be given to of retreatment more information is In patients have and retreatment more treatment with with for is more data are In the of for patients in whom prior treatment with be given to in a For patients with liver disease, be given to of retreatment the of In patients retreatment more on data and the of HCV drug with or is for retreatment of patients with HCV a in in each on the data available for is that patients an need for HCV treatment, of data are available or in a with have an need for treatment a of with for of have an need for treatment a of with for 12 of of and are data to retreatment of patients treatment with has failed. of prior treatment with with for in a of which was by the of patients with liver disease have or retreatment undergo for retreatment of patients with HCV For patients an need for treatment, of retreatment is the of For patients with or an need for testing which to and to be using available For patients with no retreatment with a of with for is For patients have not have treatment with and with for is For patients have and to a is with HCV infection have a prior of for 12 treatment from 12 to in HCV patients with is data that and for 12 of with for and is an for patients are no data are available to support a for patients have treatment with a be given to of retreatment more information is with HCV infection in whom prior and treatment has be with and for 12 patients to patients with with and for 12 is an for patients in whom prior and treatment are to with HCV infection have a prior of for with and for 12 is with is for to This be in patients with HCV infection have a prior of and with HCV infection in whom prior and treatment has and for 12 for patients are to and for for are to retreatment for patients with HCV for patients in whom retreatment is prior of and are for 12 and for 12 for patients and for 12 or for with were with for had than for 12 for with of treatment is for retreatment of patients with a in of for 12 or of and for 12 for 12 and for 12 for patients are to and for and data are available to for patients with HCV or in whom prior has failed. on is with HCV or infection in whom prior and treatment has of for 12 and for 12 for patients are and Antiviral be prior to treatment, and of treatment in to the of liver disease and the and safety of HCV The are in to Antiviral of with is prior to HCV The are 12 prior to panel and and is used The testing is at time prior to HCV and HCV in the that a of C Antiviral or are as treatment to and to for and with The testing is and panel are of treatment and as is 12 for patients for complete for patients is as HCV testing is of and at 12 of Antiviral drug not be or HCV are not or available HCV testing can be at the end of treatment and or the of of is for (1) a in at or (2) in of than at that is by or or by or in of than at be and at and for of of of If HCV is at of treatment, HCV testing is of treatment If HCV has by than on testing at of HCV treatment is The of a HCV at that at or is to or can be at this C not of of the treatment or or are treatment have liver and have the to Such patients be for liver disease, to and for in whom treatment be for and of and be for treatment treatment is Such patients have a virus that is to or more of the used at the time of is no to that the of more liver than the of such retreatment with the of to or more with the of testing for the at in patients with HCV infection treatment with and or treatment with in patients with testing for initial treatment is not data that for in patients treatment with is for to the months to 12 months with a complete and for with testing months for patients with or for is for retreatment as monitoring for HCV drug or is not prior to treatment of (1) with HCV infection are for treatment with with and or or (2) with HCV infection were with an and are for have HCV in the 12 or more of treatment are to have an In these patients, hepatitis liver at for liver disease, such as liver or liver with at for developing of liver with of liver in not patients with an of of patients liver an care that is for patients were with patients with liver or an liver disease the of and is have or to be at for development of an is than the with liver in most patients an and from is patients with undergo for of and these be or as in whom an is have of liver disease with or liver disease, or hepatitis at for of is that such patients be the of liver disease and for liver disease testing is for patients with for HCV infection drug or or HCV in liver of with HCV a new in most patients an testing for HCV be with an that HCV a HCV with or hepatitis infection experience and hepatitis treatment or This not with hepatitis C HCV testing treatment or of treatment is not an the For patients no is with or undergo for with to for is in whom are be and as of other of liver disease for patients have liver an for HCV or is the patient has for HCV infection or In such a HCV than an is to for HCV or monitoring for HCV infection patients an and are treatment is not with HCV have or or be to a is experienced in the management of liver disease and HCV treatment in a liver and data support the of in patients with or patients with HCV or with or C and as for 12 or had a of and is an for patients with are with HCV or For patients with are liver the of on for is of in this is of are no data from of in patients with treatment for patients with or HCV and or or or not be for liver with and of as for 12 For patients with or for For patients in whom prior treatment has and of as for and In patients with HCV infection and for liver were with for to At 12 of the patients had liver had HCV with of HCV patients experienced of whom had HCV for than of the patients with HCV or These data that and can be given to liver with and treatment for patients with or and or or or not be for liver with and of the and for to HCV Liver and In a of liver with or were to and for 12 or In the and was in of patients with to and was in or C with no in with all patients the is that to the on other of is an for In a of liver with of HCV for an of of the and are for and In a of with or in liver the was not be with be with with for and patients with HCV or infection in the with of with for 12 for patients with HCV or infection in the of for is for are or not or For patients with HCV in the with with or for 12 For patients with HCV in the of and for data are available to treatment of patients with HCV or in the recommendations in the and patients with HCV in the with and for and patients with HCV in the the and for or and initial of as for The approved can be in with are data to of these in disease of with or HCV or in patients with is in managing to and not be given the is than 10 For patients with to no is using of or of to or HCV infection in patients with For patients with HCV and with treatment with the of with or is be given the is For patients with initial be or other For patients with or are on initial be to with HCV infection with have a of HCV to and liver disease, and HCV with had to and than with HCV infection an by the HCV with the of in treatment and patients have not been the treatment recommendations for are the as for with HCV infection, with of with HIV In testing has been in and is experience with the In the is or on The with the of is of the of are by and be with of other that the of of in the HIV other and be HCV treatment is In was with and and with of the was with to were and not be used with the have the safety and of in with HCV or were that and with or are from that HCV and as as with or data in with HCV or infection have the safety and of for 12 and of with or for 12 on treatment of with HCV or support of as are for HIV of and with or were for and was be and the as HIV infection, and managing with treatment to HCV is not and HCV drug be prior to be in with the HIV For HIV and HCV not is The are recommendations to drug which need to be in and be in with of this is is used with HIV be with this be and the of treatment is and of not be used with and or not be used with be used with with which not have and The of used for HIV need to be with and HCV treatment is The HIV be at the time as the HCV not be used with or not be used in are not not be used with or HIV be used with with which not have and not be used with or HCV with HCV is to be the first of than in of in than infection for the first months of HCV infection, is a to in patients with and HCV of HCV infection to from in which is a such as a care with a is often to infection the to this is HCV infection can be of from infection would be for The of to HCV infection is on the of the of to the and safety of treatment in the with the of infection, and patient was were HCV infection was the first than a the of in the first treatment was that for treatment of infection are than and to to or by the patient or for other with HCV infection be for or more If has not treatment the recommendations as for treatment is than months infection, is to at least 12 for and the as with infection the of The optimal and of monitoring in infection on the treatment and is of At a HCV be months the of infection to infection more testing of HCV and liver is The are in the and initial management of hepatitis HCV and HCV testing are HCV infection is to or monitoring for is in the of HCV infection the and HCV If a has been made to treatment the infection monitoring HCV for at least is to If the and patient have that a in treatment is monitoring for is for a of is for patients with HCV infection to and and to the of HCV to to an medicine is for patients with HCV infection to drug use. of with hepatitis C be the as that for HCV infection and in to HCV with or for with HCV or have a to with HCV HCV Panel and Panel in the of This of and of Liver of of of Department of Health of and for Health The of at of of and of Infectious Diseases The of of of of and of Liver of and of Liver of and of Liver of Liver Diseases of and and Diseases of Health of Infectious Diseases and of of of of and for and of of and of and of of and of Human of of of and of the of of of of for and for and of of of of Infectious Diseases of of and of of the of Infectious Diseases of of and of the of Diseases of of of and of the The of of and of of of the of for and for and of of HCV Panel has no to was research to from and on data and safety monitoring boards for as of and not hepatitis updated has no to has no to was research to from and from from Panel has no to on the advisory boards of or as a to and was research to from and International on the advisory boards of and was research to from and on a data and safety monitoring for and as a to was research to from and has no to on the advisory boards of and was research to from and has no to on the advisory boards of and was research to from and has no to was research to from and has no to has no to was research to from and October on an advisory for was research to from and has no to has no to was research to from and on advisory boards for and was research to from and has no to was to from and on the advisory boards of and and as a for was research to from and as a to and has from has from was research to from and has for advice or data safety monitoring from and on a data and safety monitoring for and and has on the advisory boards of and was research to from and on the advisory boards of and has on data and safety monitoring boards for was research to from and has no to was research to from and has no to on the advisory of was research to from and